Review
Evaluation
Target price
Dynamics
Performance
Growth
Dividends
Risks
CN¥ 7.42
Key Takeaways
Risk factor
Resilient to price shocks
Data is available to registered users only
Data is available to registered users only
Profitability factor
Greatly overvalued vs peers
Data is available to registered users only
Data is available to registered users only
About
Jinling Pharmaceutical Company Limited manufactures and sells pharmaceutical products in China. The company offers Mailuoning injection for the treatment of thrombo-occlusive vasculitis, arteriosclerotic occlusive disease, cerebral thrombosis and sequelae, multiple arteritis, acute arterial embolism of the limbs, diabetic gangrene, venous thrombosis, thrombophlebitis, etc.; ferrous succinate tablets for the prevention and treatment of iron deficiency anemia;...
Company Valuation
Considering past and projected metrics, the stock is distinctly 'expensive' compared to its peers. In particular, the stock is overpriced on P/E, 'expensive' on EV/EBITDA
Data is available to registered users only
Buy
Sell